A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations
Latest Information Update: 20 May 2025
At a glance
- Drugs SW 682 (Primary)
- Indications Mesothelioma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors SpringWorks Therapeutics
Most Recent Events
- 13 Jun 2024 Status changed from not yet recruiting to recruiting.
- 01 Feb 2024 Status changed from planning to not yet recruiting.
- 10 Jan 2024 New trial record